Tekla Capital Management co-led the Series C round for the orthopaedic implants company, which is backed by SR One, the corporate venturing unit of UK-based healthcare company GlaxoSmithKline.
IIluminOss Medical, a developer of photodynamic orthopedic implants backed by SR One, GlaxoSmithKline’s corporate venturing unit, has raised $28m in Series C funding for minimally invasive bone fracture repair.
Tekla Capital Management, the investment advisor to H&Q Life Sciences Investors and H&Q Healthcare Investors (The H&Q Funds) and life science investment firm, Life Sciences Partners, co-led the round.
Excel Venture Management, Pappas Ventures and the Slater Technology Fund also invested in the medical device company. They were joined by return backers…
